Quantcast
Home > Quotes > FOLD

Amicus Therapeutics, Inc. Common Stock (FOLD) Quote & Summary Data

FOLD 
$9.84
*  
0.23
2.28%
Get FOLD Alerts
*Delayed - data as of Aug. 23, 2019  -  Find a broker to begin trading FOLD now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 10.245 / $ 9.76
Share Volume
2,542,574
50 Day Avg. Daily Volume
3,353,880
Previous Close
$ 10.07
52 Week High / Low
$ 14.615 / $ 8.27
Market Cap
2,505,520,460
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
2,542,574
50 Day Avg. Daily Volume:
3,353,880

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.17

Trading Range

The current last sale of $9.84 is 18.98% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 10.245 $ 14.615
 Low: $ 9.76 $ 8.27

Company Description (as filed with the SEC)

We are a global patient-dedicated biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases. With one medicine for Fabry disease achieving global approval, a differentiated biologic for Pompe disease in late-stage clinical development and fourteen gene therapy programs in the pipeline, including two clinical stage gene therapies for Batten disease, we have a leading portfolio of therapies for lysosomal storage disorders ("LSDs"). The cornerstone of our portfolio is GalafoldĀ®, (also referred to as "migalastat HCl" or "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, or mutations. GalafoldĀ® is currently approved in the United States ("U.S."), European Union ("EU") and Japan, with additional approvals granted and applications pending in several geographies.  ... More ...  



Risk Grade

Where does FOLD fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 10.07
Open Date:
Aug. 23, 2019
Close Price:
$ 9.84
Close Date:
Aug. 23, 2019


Consensus Recommendation

Analyst Info